Purpose Both carbon monoxide (CO) and nitric oxide (NO) are two gaseous molecules performing relevant functions in mammals. In order to better understand their actions in the cardiovascular system, we have investigated the effects of CORM-3, (tricarbonylchloro(glycinato)ruthenium(II), a water soluble CO-releasing molecule and SNAP (S-nitroso-Nacetyl-DL-penicillamine, a well known NO-releasing molecule) on aortas of normotensive Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). Methods The isometric contraction of angiotensin II (AT-II) and endothelin-1 (ET-1) was evaluated in endotheliumdenuded aortic strips. Results In control conditions, AT-II induced a similar concentration-dependent contraction in both WKY and SHR, while ET-1 was more effective in SHR aortic strips. CORM-3 or SNAP (10 −7 -3×10 −4 M) reduced the contraction induced by AT-II or ET-1 in a concentration-dependent way. Whereas the median inhibitory concentration of SNAP was significantly lower in WKY than in SHR, CORM-3 had a similar effect in both strains. The scaffold compound iCORM-3 was ineffective. Pretreatment with an inhibitor of soluble guanylyl cyclase (ODQ, 3×10 −6 M) marginally reduced CORM-3 relaxation in both strains, whereas it reduced relaxation induced by SNAP in WKY and, to a lesser extent, in SHR. The benzylindazole derivative YC-1 (10 −6 M), a sensitizer of soluble guanylate cyclase to the action of NO, significantly increased the relaxant effect of SNAP in AT-II precontracted aortic strips. The blocker of calcium-activated potassium channels, charybdotoxin (10 −8 M), reduced the relaxation induced by CORM-3 in both strains.
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Conclusions Different mechanisms seem to be implicated in CO-and NO-mediated vascular relaxation. Since the relaxant properties of CO are conserved in SHR aortas, CORM-3 could be a new potential agent for the treatment of hypertension, when NO donors show sub-optimal or absent responses.
Introduction
Mammalian cells constantly generate carbon monoxide (CO) gas via the endogenous degradation of heme by a family of constitutive (HO-2 and HO-3) and inducible (HO-1) heme oxygenase (HO) enzymes [1] . CO is a versatile signalling molecule with essential regulatory roles in a variety of physiological and pathological processes [2] [3] [4] In the cardiovascular system, CO exerts an important relaxant effect [5] which is shared with the endothelium-derived relaxing factor nitric oxide (NO) generated by the constitutive isoform of endothelial NO synthase (eNOS) [6] . CO, like NO, activates soluble guanylate cyclase [7] , although its effect is less potent than that exerted by NO [8, 9] . Although this mechanism contributes to the relaxant effect of CO, it has been demonstrated that CO can directly activate big-conductance calcium-activated potassium channels (BK channels) [10] , resulting in membrane hyperpolarization and relaxation in precontracted arteries.
These findings have prompted many researchers to consider CO as a potent therapeutic tool in the treatment of vascular dysfunction, leading to the synthesis and characterization of CO-releasing compounds, among which are transition metal carbonyl compounds capable of carrying and delivering CO into biological systems and possessing vasodilatory properties [11] .
Systemic hypertension impairs vascular tone, increases arterial blood pressure and is a major risk for patients with cardiovascular diseases. While the physiological and pharmacological role of NO in hypertension is well established, that of CO in this pathological condition is less clear.
Thus, the purpose of this study was to assess the effect of the water soluble carbon monoxide-releasing molecule CORM-3 [12, 13] on aortas of control normotensive Wistar Kyoto (WKY) and spontaneously hypertensive (SHR) rats in comparison with S-nitroso-N-acetyl-DL-penicellamine (SNAP), an NO donor. Angiotensin-II (AT-II) and endothelin-1 (ET-1) are very potent contractile agonists of the vasculature system, both of them implicated in human hypertension. Their contractile action on vascular smooth muscle cells is mediated via an increase in cytosolic Ca 2+ . However, mechanisms of this process are different between the two agents.
Endothelin-1 increases intracellular Ca 2+ by stimulating influx through Ca 2+ channels [14] and is known to produce a much more sustained contraction by the vascular smooth muscle cells, whereas angiotensin II elicits a biphasic response that is generated primarily by mobilization of Ca 2+ from intracellular stores followed by Ca 2+ entry [15] . Given the different mechanisms for smooth muscle contraction of these agonists, we decided to investigate the relaxant effect of NO and CO on preparations precontracted with AT-II or ET-1.
Methods

Synthesis of CORM-3 and other chemicals
CORM-3 was synthesized as described previously [12, 13] and was prepared as a 10 mM stock by dissolving the compound in pure distilled water. It was kept at −20°C and defrosted before each experiment. Final concentrations of CORM-3 were prepared immediately before their use.
Inactive CORM-3 (iCORM-3) was obtained by leaving CORM-3 in phosphate buffer saline (PBS), pH 7.4 at room temperature overnight to permit the release of all available CO from the molecule [12] . This treatment produces an inactive carrier molecule that no longer releases CO (iCORM-3), which was used as a negative control [13] .
Angiotensin II (AT-II), endothelin-1 (ET-1) and charybdotoxin (CHTX) were purchased from Sigma Chemical Detection of carbon monoxide (CO) release from CORM-3 and iCORM-3
The amount of CO liberated by CORM-3 and iCORM-3 was measured with an ultra-trace gas detection system (RGA3, Reduction Gas Analyzer, SAES Getters, Milan, Italy) dedicated to CO detection as already described [16] with few modifications. Briefly, 2 ml of PBS solution (pH 7.4) containing different concentrations of CORM-3 and iCORM-3 (10 nM-1 mM) were incubated at 37°C in sample vials. The gas developing in 2 min was collected in the headspace of the vial and transferred to the reduction gas analyzer via a two-needle assembly attached to the injection valve. This valve was controlled by a timer. The head space gas components were separated chromatographically within an isothermal mandrel-heating column oven at a temperature of 100°C with CO-free air carrier gas (N 2 70 cc/min). Species eluting from the chromatographic column passed immediately into the detector. CO was quantified in the detector by means of A 254 of Hg generated from the reaction of CO with HgO at 225°C. A 10-mV recorder charted the detector response in terms of peak height at a paper speed of 10 mm/min. Peak heights and areas were used to correlate detector response between standards and unknowns. A CO standard curve was prepared immediately prior to sample analysis. Standard gas was obtained from a commercial source (Rivoira, Milan). The method allowed the precise determination of the CO amount developed by the studied molecules. Functional studies on rat thoracic aortas Thoracic aortas were isolated from WKY and SHR and, after removing the endothelium by rubbing the cell layer with a cotton swab, were mounted in an organ bath of 2 ml volume [17] . The strips were perfused with pre-warmed (37°C) KrebsHenseleit solution, (pH 7.4) of the following composition (mM): 110 NaCl, 25 NaHCO 3 , 4.8 KCl, 1.2 KH 2 PO 4 , 1.2 MgSO 4 , 11 (+) glucose, 2.5 CaCl 2 , and gassed with 5 % CO 2 in O 2 . The resting tension applied to the aorta preparation was 0.7 g.
After 60 min of stabilization, the absence of endothelium was tested as previously reported [18] , and cumulative concentration-response curves of AT-II or ET-1 were performed in different aortic preparations. Then, strips were extensively washed, re-stabilized and precontracted using the maximal contracting dose of AT-II or ET-1 (100 % of contractile response). Cumulative concentration-response curves of either CORM-3 or SNAP were performed in control conditions or after the preincubation (30 min, 37°C) with 3×10 −6 M ODQ or 10
The effects of CORM-3 and SNAP on vascular relaxation were also assessed in the presence of the soluble guanylate cyclase stimulator, YC-1 (10 −6 M, which was added 30 min before AT-II or ET-1).
Determination of cyclic GMP levels
Wiped, frozen arteries from WKY and SHR obtained from the different experiments were homogenized in 6 % trichloroacetic acid (TCA) and the samples were centrifuged at 2,000 × g for 15 min. at 4°C. The precipitate was discarded and TCA was removed from the supernatant by extraction with 5 ml of ether (three times 
Results
Detection of CO release from CORM-3 and iCORM-3
The release of CO from CORM-3 solution at different concentrations (pH07.4, 37°C) is reported in Fig. 1 . As shown, the CORM-3 solution spontaneously released CO in a concentration-dependent way in the range from 10 nM to 10 mM. Predictably, iCORM-3 did not release CO at all the tested concentrations, as reported in Fig. 1 .
Effect of ET-1 and AT-II on isolated aortas
We tested the contractile effect of AT-II and ET-1 on endothelium denuded aortas isolated from WKY and SHR. The AT-II in evoking contraction in both strains, its effect being significantly higher (p<0.001) in aortas isolated from SHR than WKY, even if ET-1 full contractility was obtained at 10 −8 M in both strains (Fig. 2b) .
Vasodilatatory effects of CORM-3 and SNAP in aortic rings isolated from WKY and SHR rats
It has been shown that CORM-3 promotes rapid and significant relaxation in rat aortic rings precontracted with phenylephrine, its effect being mediated by CO [15] . Therefore, we tested the effect of CORM-3 on aortic strips isolated from WKY and SHR and precontracted with 10 −7 M AT-II or 10 −8 M ET-1. CORM-3 relaxed precontracted aortic preparations from both strains, its maximal effect occurring at 10 −4 M when AT-II was used as contractile agonist (Fig. 3a) and 3×10 −4 M (the maximal concentration usable in our protocol) in ET-1 contraction (Fig. 3b) . The CORM-3 concentration-dependent curves were similar at all concentrations tested, independently of the rat strain and contractile agonist used. This comparable effectiveness of CORM-3 in WKY and SHR was also reflected by the median inhibitory concentrations (IC50s) on 10 −7 M AT-II, and in 10 −8 M ET-1 precontracted preparations (Table 1 ). In parallel experiments, AT-II or ET-1 precontracted aortic strips were also treated with 300 μM iCORM, the inactive compound which was totally ineffective (data not shown).
Compared to the NO releaser SNAP, CORM-3 showed reduced activity in relaxing WKY aortic preparations, but a similar effectiveness in SHR at all concentrations tested (Fig. 3, panel A and B) . To note that SNAP was significantly less potent in SHR than WKY preparations: indeed, the IC50s were about 9 and 6 fold higher in SHR than in WKY in AT-II and ET-1 precontracted preparations respectively (Table 1) . On the other hand, CORM-3 showed a similar potency in SHR and WKY preparations and, in SHR aortic strips, its IC50s tending to be lower than those calculated for SNAP in the same strain.
CO-mediated vasorelaxation by CORM-3: possible mechanisms of action
It is well established that CO, endogenously generated from HO-1, exogenously applied as CO gas or delivered by CORMs, behaves by activating several intracellular targets and these actions are shared with NO. For example, activation of soluble guanylyl cyclase [7] and potassium channels [10] has been demonstrated for both CO and NO. Therefore, we performed experiments in order to ascertain the possible multiple mechanisms in the relaxation induced by CO and NO of aortic strips precontracted with AT-II and ET-1. To further investigate the involvement of soluble guanylyl cyclase in mediating the effect of CO and NO, we evaluated the levels of cGMP in aortic preparations isolated from WKY and SHR and preincubated with 3×10 −4 M CORM-3 or 10 −5 M SNAP ( Table 2) . The benzylindazole derivative, YC-1 is known to sensitize soluble guanylate cyclase to the action of NO [19] . When aorta preparations were pre-incubated with 10 −6 M YC-1 and precontracted with AT-II, the relaxing effect of SNAP was significantly increased at all concentrations tested in preparations isolated from WKY and, to a lesser extent, in SHR (Fig. 4, panels A and B) ; on the contrary the sensitizing action of YC-1 on the relaxing effect of CORM-3 was practically absent in preparations isolated from both strains (Fig. 4) . The BK channel blocker CHTX (10 −8 M) reduced CORM-3 relaxation in WKY and SHR preparations precontracted with AT-II or ET-1 and shared a similar or higher effectiveness than ODQ in reducing CORM-3 relaxation (Figs. 4 and 5, panels A and B). However, CHTX was less effective than ODQ in reducing SNAP relaxation of WKY precontracted with AT-II (Fig. 4 , panel C), but it was similarly effective when the contraction was induced by ET-1 (Fig. 5, panel C) . Moreover, SNAP relaxation was reduced by CHTX more efficiently in WKY than in SHR aortic strips precontracted with both agonists (Figs. 4 and 5 , panels C and D). 
Discussion
The present study shows that tricarbonylchloro(glycinato) ruthenium(II), CORM-3 promotes significant relaxation in aortas isolated from WKY and SHR and precontracted with AT-II or ET-1.
CORM-3 as already demonstrated is a highly water soluble, rapid CO releaser molecule [12, 13] . As measured by reduction gas analyzer, CORM-3 can release CO in a concentration-dependent fashion. Although the CO quantity detected is lower than the CORM-3 concentration used, this measurement allows to perform concentration-response curves with CORM-3 on biological preparations.
Like NO, CO is a relaxing factor which induces relaxation of vascular muscle cells by several mechanisms including the stimulation of soluble guanylate cyclase/cGMP/ cyclic dependent protein kinase I pathway and various types of potassium channels [3, 8] . All these mechanisms can contribute in a different way to the final relaxation according to the different vascular districts, contractile agents used and patho-physiological experimental models.
Vascular tissue isolated from SHR is a widely used model of experimental hypertension, even if it represents a genetic form of hypertension and therefore it reflects only a subtype of human hypertension. On the other hand, several naturallyoccurring cardiac and renal derangements in SHR, especially older ones, are very similar to those observed in human essential hypertension [20] . Therefore, studies in this hypertensive animal model can suggest useful information on the action of pharmacological agents. Moreover, early studies on 7-week old SHR demonstrate that a 4 day treatment with stannous chloride (SnCl2) can increase HO-1 activity in the kidney and decreases blood pressure [21] . However, the blood pressure is not modified by a similar treatment in 20-week old animals. These results suggests that CO may lower blood pressure.
In our study we tested the relaxing effect of CORM-3 and SNAP in endothelium denuded precontracted aortic preparations, isolated from SHR and WKY rats. It is well known that endothelium is the major source of NO [6] . Therefore, in its absence it is unlikely that endogenous produced NO can influence the effect of both exogenous vasodilators.
CORM-3 and SNAP relax aortic strips precontracted with both AT-II and ET-1 in a concentration-dependent way although the vasodilator responses induced by CORM-3 and SNAP are different in the four studied groups. In particular, both relaxing agents are less effective when aortas are contracted with ET-1 that, according to literature data [22] , produces a much stronger contraction than AT-II as a result to its different Ca 2+ mobilizing mechanisms [14, 15, 22] . Particularly in SHR, its maximal effect is significantly higher than in WKY aortas. Therefore, the reduced effectiveness of both CORM-3 and SNAP in ET-1 precontracted preparations could be related to the stronger contraction induced by ET-1. In preparations isolated from WKY rats, CORM-3 is less potent than SNAP in relaxing AT-II or ET-1 -precontracted preparations, but CORM-3 shows a similar effectiveness in SHR aortic strips. Whereas the SNAP-induced relaxation is significantly decreased in preparations from SHR as compared to WKY ones, the vasodilator response to CORM-3 is of the same extent in both strains as demonstrated by their IC50s.
The SNAP-induced relaxation is strongly decreased by ODQ and this effect is particularly evident in WKY where it decreases relaxation at all SNAP concentrations used. On the other hand, CORM-3 relaxation is only affected by ODQ at high CORM-3 concentrations (10 −4 -3×10 −4 M), suggesting that different pathways may predominate in SNAP and CORM-3 relaxation, at least at low CORM-3 concentrations. It seems that in our experimental conditions, the cGMP pathway is the prominent mechanism involved in the SNAP effect, but it plays a less important role in CORM-3 relaxation. The experiments performed by preincubating the aorta preparations with YC-1, a soluble guanylate cyclase sensitizing agent confirmed this hypothesis. It should also be remembered that CO activation of soluble guanylate cyclase differs by several orders of magnitude from that elicited by NO [8, 9] . In agreement with these data, our results show a significant increase in cGMP content after 3×10 −4 M CORM-3 or 10 −5 M SNAP treatment of isolated aortas, while NO, at a low concentration, was more effective than CO in increasing cGMP in WKY rats. This different sensitivity of soluble guanylate cyclase activation by NO and CO could explain why ODQ prevents relaxation only at a high CORM-3 concentration. In preparations isolated from SHR, the increase in cGMP induced by SNAP is significantly lower than in those isolated from WKY rats as well as the relaxation induced by SNAP of precontracted aortas. This result is not unexpected, since the cGMP pathway is impaired in SHR. Soluble guanylate cyclase and cGMP-dependent protein kinase expression are decreased in SHR aortas [23] and functionally, SNAP and the membrane-permeable dibutirryl cyclic GMP do not regulate intracellular calcium concentrations in aortic smooth muscle cells isolated from SHR [24] . CHTX is at least similar or more effective than ODQ in reducing CORM-3 relaxation in both SHR and WKY aortic strips, but less active in inhibiting SNAP relaxation, suggesting that potassium channels are chiefly involved in CO relaxation, but represent a secondary pathway in NO relaxation. CO and NO can activate potassium channels with different modalities [25] . In particular, the stimulatory effects of CO depends on specific interaction with the α-subunit of the calcium activated potassium channel (KCa,α), while NO activation relies on β-subunit (KCa,β), although it can also bind the α-subunit [25] . Pioneer studies on aortas and aortic isolated smooth muscle cells of SHR [26, 27] describe an upregulation of BK that can represent a compensatory mechanism in the hypertension setting. Therefore, CO that targets potassium channels in cardiovascular pathologies, such as hypertension, can provide alternative vasodilator therapies to the traditional agents acting via direct or indirect NO production. Moreover, a recent report suggests the involvement of ATP-dependent (K ATP ) potassium channels as part of the dilatatory mechanisms exerted by CORM-3 [13] . However, other authors report the central role of the KCa,α in CO effect [25, 28, 29] .
In conclusion, an agent which can relax vasculature independently of cGMP-dependent protein kinase could represent a suitable pharmacological approach in clinical situations where the response to NO is sub-optimal. In this perspective, although less effective than SNAP in physiological conditions, CORM-3 could be a good candidate when the NO/cGMP/cGMP-dependent protein kinase pathway is impaired.
